Acquisitions
In May 2011, Abcam announced the acquisition of MitoSciences, a privately held biotech company based in Eugene, Oregon (US).[13] The company produced and distributed immunoassay platforms and high performance monoclonal antibodies. It was founded in 2004 with the mission of advancing mitochondrial research and developing products that support critical research in cancer, neurodegeneration, and metabolic disorders.
On 12 September 2011, Abcam completed the purchase of Ascent Scientific, a company based in Bristol, United Kingdom which provided biochemical products that modulate the function of proteins for use in life science research. After outsourcing biochemical production, the Bristol site and manufacturing facilities were closed in 2017.[14]
On 19 April 2012, Abcam completed the purchase of Epitomics, a privately held biotech company in Burlingame, California (US) and Hangzhou (China) which focused on the development, production, and distribution of rabbit monoclonal antibodies for biomedical research and diagnostic applications.[15]
On 20 January 2015, Abcam announced the acquisition of Firefly BioWorks, a privately held company based in Cambridge, Massachusetts (US),[16] for GB£18500000.[17] Firefly developed a novel multiplex assay platform for the detection of biomarkers, based on a microfabrication technology developed by Daniel Pregibon and Patrick Doyle at Massachusetts Institute of Technology, and launched its first products for the multiplex detection of microRNA from RNA and crude biofluid.[17] Firefly was rebranded to FirePlex in 2016.[18]
On 11 November 2015, Abcam announced the acquisition of AxioMx.[19] AxioMx, based in Branford, Connecticut (US), "provides a comprehensive custom recombinant antibody discovery and development services platform".[20]
Abcam acquired Calico Biolabs in January 2019. A year later, on 6 January 2020, Abcam announces the successful acquisition of Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences.[21][22] On 4 March 2020, Abcam extend their assay and labelling capabilities by acquiring Marker Gene Technologies for an undisclosed amount. The acquisition of Marker Gene Technologies bring expertise in the areas of biology, organic synthesis and fluorescence chemistry. The team from MGT are experienced in the creation of detection tools that enable enhanced understanding of biological processes.[23]
